|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.010 USD | -3.37% |
|
-14.50% | -50.98% |
| Apr. 30 | Cybin Inc. will Change its Name to Helus Pharma | CI |
| Apr. 28 | Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health | CI |
Business description: Cybin Inc.
Number of employees: 50
Sales by Activity: Cybin Inc.
| Fiscal Period: March | 2021 (CAD) | 2022 (CAD) | 2023 (CAD) | 2024 (CAD) | 2025 (CAD) |
|---|
Executive Committee: Cybin Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Glavine
COO | Chief Operating Officer | 37 | 2016-10-12 |
Eric So
CEO | Chief Executive Officer | 51 | 2026-04-19 |
Greg Cavers
DFI | Director of Finance/CFO | 56 | 2020-11-04 |
Aaron Bartlone
COO | Chief Operating Officer | 59 | 2023-06-30 |
Alex Nivorozhkin
CTO | Chief Tech/Sci/R&D Officer | 66 | 2020-11-30 |
Composition of the Board of Directors: Cybin Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Eric So
CHM | Chairman | 51 | 2020-11-04 |
Paul Glavine
BRD | Director/Board Member | 37 | 2016-10-12 |
Eric Hoskins
BRD | Director/Board Member | 65 | 2020-11-04 |
Mark Lawson
BRD | Director/Board Member | 54 | 2020-11-04 |
Grant Froese
BRD | Director/Board Member | 64 | 2020-11-04 |
| Director/Board Member | 70 | 2021-08-15 | |
Freda Lewis-Hall
BRD | Director/Board Member | 71 | 2026-02-23 |
Company details: Cybin Inc.
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.37% | -14.50% | -54.94% | -55.10% | 208M | |
| -0.37% | +6.30% | +47.85% | +109.38% | 55.01B | |
| -0.58% | -3.99% | +50.00% | +49.74% | 43.37B | |
| -2.93% | -6.76% | -21.19% | -21.54% | 22.27B | |
| -0.05% | -11.19% | +27.91% | +370.14% | 20.42B | |
| -4.02% | -17.13% | +12.00% | -35.07% | 17.27B | |
| +1.74% | -1.71% | +11.45% | -40.07% | 15.02B | |
| -1.82% | +2.90% | +20.24% | +167.39% | 13.25B | |
| +1.62% | -4.01% | +12.62% | - | 11.71B | |
| -4.47% | -10.18% | -31.47% | +666.85% | 11.46B | |
| Average | -1.46% | -5.64% | +7.45% | +134.64% | 21B | |
| Weighted average by Cap. | -1.03% | -2.93% | +25.34% | +120.52% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HELP Stock
- Company Cybin Inc.
Select your edition
All financial news and data tailored to specific country editions
